The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•4 May 2026•

1 min read

BMO Capital Maintains Market Perform Rating for Bristol-Myers Squibb with $60 Target

Key Facts

1BMO Capital reiterated its Market Perform rating for Bristol-Myers Squibb with a $60.00 price target.

2The company faces future revenue pressure from losses of exclusivity for legacy products like Revlimid and Eliquis.

BMO Capital has reiterated its Market Perform rating for Bristol-Myers Squibb (BMY), maintaining a price target of $60.00 per share. The rating reflects a strategic balance between the stock's current valuation and significant upcoming revenue headwinds. Analysts highlighted that the pharmaceutical giant faces mounting pressure as legacy blockbuster products, including Revlimid and Eliquis, lose their patent exclusivity. Future growth prospects for the company are now heavily contingent on the success of upcoming clinical trial results for its new pipeline. Consequently, BMO Capital maintains a neutral stance until there is more clarity on the company's ability to offset the looming patent cliff. Investors are closely watching how the firm navigates these transitions to sustain its long-term market position.